Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Artrya Limited ( (AU:AYA) ) has issued an update.
Artrya Limited has announced its upcoming Annual General Meeting scheduled for November 13, 2025, in West Perth, where shareholders will review the company’s financial statements and reports for the year ending June 30, 2025. Key resolutions include the adoption of the Remuneration Report and the re-election of Catherine Hill as a Director. These decisions are pivotal for the company’s governance and strategic direction, impacting shareholder interests and corporate leadership.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited operates in the healthcare industry, focusing on the development of advanced medical technologies for the diagnosis and management of coronary artery disease. The company is dedicated to improving patient outcomes through innovative solutions that enhance the detection and treatment of heart-related conditions.
Average Trading Volume: 676,761
Technical Sentiment Signal: Buy
Current Market Cap: A$414.7M
For an in-depth examination of AYA stock, go to TipRanks’ Overview page.